Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01723020 · ClinicalTrials.gov registry record · Phase 1
A Phase 1 Study Evaluating AMG 232 in Advanced Solid Tumors or Multiple Myeloma
A Phase 1 study, sponsored by Kartos Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 107
- Enrollment target
NCT01723020 is a Phase 1 study that has completed, run by Kartos Therapeutics. The registered enrollment target is 107 participants.
The verdict
NCT01723020, a Phase 1 study, has completed, sponsored by Kartos Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 107 participants
- Enrollment target
Study Summary
First in human, open-label, sequential dose escalation and expansion study of AMG 232 in subjects with advanced solid tumors or multiple myeloma
Interventions
- DRUG AMG 232
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 107 participants |
| Start Date | 2012-12-27 |
| Est. Completion | 2017-09-25 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01723020
The ClinicalTrials.gov registry entry for NCT01723020 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 107 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Kartos Therapeutics, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which AMG 232 is the first listed.
NCT01723020 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01723020 about?
NCT01723020 is a clinical study titled "A Phase 1 Study Evaluating AMG 232 in Advanced Solid Tumors or Multiple Myeloma". First in human, open-label, sequential dose escalation and expansion study of AMG 232 in subjects with advanced solid tumors or multiple myeloma
What is the current status of trial NCT01723020?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 107 participants. The study started on 2012-12-27. Estimated completion is 2017-09-25.
What interventions are being tested in trial NCT01723020?
The interventions under investigation include: AMG 232 (DRUG).
Who is sponsoring clinical trial NCT01723020?
This trial is sponsored by Kartos Therapeutics, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.